<SEC-DOCUMENT>0000950170-25-019314.txt : 20250213
<SEC-HEADER>0000950170-25-019314.hdr.sgml : 20250213
<ACCEPTANCE-DATETIME>20250213060508
ACCESSION NUMBER:		0000950170-25-019314
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250213
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250213
DATE AS OF CHANGE:		20250213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IDEAYA Biosciences, Inc.
		CENTRAL INDEX KEY:			0001676725
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				474268251
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38915
		FILM NUMBER:		25616975

	BUSINESS ADDRESS:	
		STREET 1:		5000 SHORELINE CT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-443-6209

	MAIL ADDRESS:	
		STREET 1:		5000 SHORELINE CT, SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ideaya Biosciences, Inc.
		DATE OF NAME CHANGE:	20160609
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>idya-20250213.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-12T21:00:59.0185+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:idya="http://www.ideayabio.com/20250213" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_5080a650-be67-4562-a708-c0174506f6b9" name="dei:EntityCentralIndexKey" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763">0001676725</ix:nonNumeric><ix:nonNumeric id="F_be4fe8f3-19cd-4308-9f54-72b32d444c76" name="dei:AmendmentFlag" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="idya-20250213.xsd"/></ix:references><ix:resources><xbrli:context id="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001676725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-13</xbrli:startDate><xbrli:endDate>2025-02-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68606d89-c67e-4cac-b63f-567c02e842fd" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a372119-1541-4907-a056-ba16b4004863" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 13, 2025</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33e93ea2-fc5e-429d-8ca8-03bd9b0c74d6" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:39%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1a776c9e-ad9b-4740-8c96-b64a015b16a3" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9b114dc7-d389-49b8-8898-06760a6433e2" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-38915</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2d65fe38-2ce0-41d3-b3f4-e66cbda0dd7f" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47-4268251</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File Number)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification Number)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed2fe6ad-13ab-42bf-a31f-07963cf3f87c" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5000 Shoreline Court</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4175a373-b228-4594-b75d-d1439d19e58e" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 300</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7848364a-b426-4bae-a528-1b452777ed6c" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4c56b77-cb4f-4deb-82ab-fb0babff8bc4" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf2eebeb-f0c1-4e3f-a69b-5c2424a33434" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94080</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of principal executive offices, including Zip Code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6eb8dd52-db95-41e8-9614-167aa0b70db3" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d7e86bd-f523-430c-8706-ace50da3e23c" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">443-6209</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2eb28740-2042-445f-ab2c-a0c91d1edcbb" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e50047a6-7c07-4c73-b684-9d95a0e0e77a" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6dba4e91-3f84-420d-9e1e-ca2917ce8400" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef1d3990-9392-47d4-a276-96148fe18815" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered or to be registered pursuant to Section 12(b) of the Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:39%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ea64606a-7380-4661-99d1-62f6a0483ca8" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_5c44f9e8-aa37-438a-9445-d787b885798e" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">IDYA</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_145a09d1-8542-42f6-87ad-9c45057e5aff" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1be958f-4e60-47c3-ad7c-4735cb80a935" contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2025, IDEAYA Biosciences, Inc. (the &#8220;Company&#8221;) announced its financial results for the fourth quarter and full year ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.12%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:91.88%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0in;text-indent:6.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="idya-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release dated February 13, 2025.</span></a></p></td>
   </tr>
   <tr style="height:7.2pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;text-indent:6.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;text-indent:6.75pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:3%;box-sizing:content-box;"/>
    <td style="width:47%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">IDEAYA BIOSCIENCES, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 13, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Yujiro Hata</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Yujiro Hata</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>idya-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">and Provides Business Update</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">95 patients enrolled in neoadjuvant UM trial and targeting clinical data and regulatory update(s) in H1 2025, including vision data in plaque brachytherapy patients</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting median OS readout in ~40 1L MUM patients in 2025</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting expansion of study in Q1 2025 of IDE397 in combination with Trodelvy</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (sacituzumab govitecan-hziy) in MTAP-deletion UC and clinical data update in 2025; expanded clinical study collaboration into NSCLC</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting to enable wholly owned IDE397 and IDE892 (IDEAYA PRMT5) clinical combination in H2 2025; IDEAYA and Amgen mutually agree to wind down the IDE397 and AMG 193 clinical combination study</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Clinical expansion doses selected for DLL3 TOP1i ADC IDE849 by collaboration partner Hengrui, and targeting clinical data update and combo initiation with IDE161 in 2025</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Ph1 initiated for Werner Helicase IDE275 (GSK959) and received $7 million milestone from GSK, and targeting medical conference update in H1 2025</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting IDE161 expansion with KEYTRUDA</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (pembrolizumab), Merck's anti-PD-1 therapy, and combo(s) with TOP1i ADCs in solid tumors in 2025 </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting 2025 INDs: IDE892 (PRMT5); IDE034 (B7H3/PTK7 ADC); IDE251 (KAT6/7)</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">~$1.1 billion of cash, cash equivalents and marketable securities as of December 31, 2024, anticipated to fund operations into at least 2028</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">South San Francisco, CA, February 13, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x2013; IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics</font><font style="color:#4a4a4a;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">announced financial results for the quarter and full year ended December 31, 2024, and provided a business update.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We are excited to be targeting multiple clinical data readouts and program updates across our clinical pipeline in 2025, including the darovasertib neoadjuvant UM data update in the first half and median PFS readout in HLA-A2 negative 1L MUM by year-end, update on the Werner Helicase inhibitor program IDE275 at a major medical conference in the first half, clinical combination results from the IDE397 and Trodelvy combination in MTAP-deletion UC where the Gilead collaboration has expanded to evaluate both UC and NSCLC, among others.  Next, we are excited to target a clinical data update for potential first-in-class DLL3 TOP1 ADC IDE849 in SCLC in 2025, including potentially at a medical conference, and we believe the clinical profile observed supports a potential monotherapy regulatory path in SCLC,&#x201d; said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;We had multiple positive clinical updates across our pipeline throughout the past year that were presented at major medical conferences, including compelling results such as tumor shrinkage and eye preservation for neoadjuvant darovasertib which was presented as an oral presentation at ASCO 2024, and evidence for monotherapy activity with IDE397 which delivered a high disease control rate and multiple confirmed RECIST 1.1 responses in MTAP-deletion lung and urothelial cancer, which was presented as a late breaker oral presentation at ENA 2024.  Next, we believe we have generated important proof-of-concept preclinically and preliminary clinical data for the MAT2A and PRMT5 combination in the MTAP-deletion setting and are excited to advance IDEAYA&#x2019;s wholly-owned IDE397 and IDE892 combination that we are targeting to have in the clinic in the second half of 2025,&#x201d; commented Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences. &#x201c;Additionally, in the last several quarters we made significant progress in enhancing our potential first-in-class clinical pipeline with the in-licensing of the Phase 1 DLL3 TOP1i ADC IDE849 and FDA clearance of the Phase 1 trial for the Werner Helicase inhibitor IDE275. We are also advancing three programs into IND-enabling studies: our PRMT5 inhibitor IDE892, the B7H3/PTK7 ADC IDE034 and a KAT6/7 inhibitor IDE251,&#x201d; said Michael White, Ph.D., Chief Scientific Officer, IDEAYA Biosciences.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Recent Key Developments and Upcoming Milestones</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Clinical Development</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Darovasertib, a potential first-in-class Phase 2/3 PKC inhibitor for the treatment of metastatic uveal melanoma (MUM) and neoadjuvant uveal melanoma (UM).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">MUM</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Independent Data Monitoring Committee (IDMC) recommended move-forward dose and the completion of the Part 2a dose optimization for the potential registration-enabling trial of darovasertib and crizotinib in first line (1L) HLA-A2-negative MUM.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting median progression free survival (PFS) readout for Phase 2/3 registration-enabling trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative MUM by year-end 2025. Rapid enrollment in the trial continues with over 230 patients as of February 7, 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.593%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.250732000879558%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Phase 2 median overall survival (OS) readout from study IDE196-001 in ~40 1L MUM patients targeted in 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Neoadjuvant UM</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">A clinical update in over 75 patients in the Company-sponsored Phase 2 trial and regulatory update(s) is targeted for the first half of 2025, including vision data in plaque brachytherapy patients. 95 patients enrolled as of December 31, 2024 in the Company-sponsored Phase 2 trial.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Initiation of the Phase 3 registration-enabling trial for darovasertib in neoadjuvant UM is targeted for the first half of 2025.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDE397, a potential first-in-class Phase 2 MAT2A Inhibitor for the treatment of MTAP-Deletion Solid Tumors.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Encouraging Phase 1 expansion results of IDE397 in MTAP-deletion urothelial cancer (UC) and non-small cell lung cancer (NSCLC) patients were presented as a </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">late-breaking oral presentation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> at the 36th EORTC-NCI-AACR Symposium (ENA 2024). Additional preclinical data on the anti-tumor activity of IDE397 and in combination with the PRMT5 inhibitors AMG 193 and BMS-986504 in MTAP-deleted tumors were presented as a </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">poster</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting Phase 1/2 expansion in the first quarter of 2025 and clinical data update for IDE397 in combination with Trodelvy</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> in MTAP-deletion UC in 2025. Entered into a Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397 in combination with Trodelvy</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> in MTAP-deletion NSCLC.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDEAYA plans to enable wholly-owned IDE397 combination with IDE892 in patients with MTAP-deletion non-small cell lung cancer (NSCLC) in the second half of 2025. IDEAYA and Amgen mutually agreed to wind down the IDE397 and AMG 193 clinical combination study in February 2025, and will not pursue dose expansion.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i antibody drug conjugate (ADC) targeting small cell lung cancer (SCLC) and neuroendocrine tumors (NETs).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDEAYA entered into an exclusive global license agreement for IDE849 outside of Greater China with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) in December 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDE849 is currently being evaluated by Hengrui Pharma in an ongoing Phase 1 trial in China in SCLC patients. In preliminary results from the trial with a data cut-off date of December 10, 2024, 8 out of 11 evaluable patients achieved partial response by RECIST 1.1, resulting in an overall response rate of ~73% (including both confirmed and unconfirmed responses, all unconfirmed responses were pending further evaluation). As of the data cut-off date, treatment related adverse events (TRAEs) were predominantly Grade 1 or 2. The most common TRAEs observed were white blood cell count decreased, anemia, neutrophil count decreased, nausea and platelet count decreased. In January 2025, Hengrui Pharma selected expansion doses for the Phase 1 trial.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDEAYA plans to submit a U.S. IND for the evaluation of IDE849 as a monotherapy in SCLC in the first half of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting to initiate the evaluation in combination with IDE161 and in NETs in the second half of 2025. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Clinical data update targeted in 2025.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDE275 (GSK959), a potential first-in-class and best-in-class Phase 1 Werner Helicase inhibitor for the treatment of high microsatellite instability (MSI-High) tumors.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Received FDA IND clearance for a Phase 1 trial in MSI-High tumors and earned a $7.0 million milestone payment from GSK.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Data highlighting IDE275's differentiated potential best-in-class profile will be presented with GSK at a medical conference in the first half of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDE161, a potential first-in-class Phase 1 PARG inhibitor for the treatment of solid tumors.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Selected initial Phase 1/2 expansion dose for IDE161 monotherapy in endometrial cancer, based on AE profile and preliminary clinical efficacy observed. Phase 1 monotherapy dose optimization is ongoing to confirm a move-forward Phase 2 expansion dose.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">First patient dosed in the Phase 1 trial evaluating IDE161 in combination with KEYTRUDA in patients with MSI-High and microsatellite stable (MSS) endometrial cancer. Targeting Phase 1 expansion in 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Highlighted preclinical data of IDE161 and antibody drug conjugate (ADC) combination rationale at a </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">poster presentation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> at ENA 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting clinical combination(s) of IDE161 with TOP1i ADCs in solid tumors in 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDE705 (GSK101), a potential first-in-class Phase 1 Pol Theta Helicase Inhibitor in combination with PARP inhibitor for the treatment of HRD solid tumors. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Targeting Phase 2 expansion in HRD solid tumors, which would trigger a potential $10 million milestone payment from GSK.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Announced three development candidates for the treatment of solid tumors:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor to enable wholly-owned combination with IDE397. IND filing targeted for mid-year 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDE034, a potential first-in-class B7H3/PTK7 TOP1i bispecific ADC with combination potential with IDE161. IND filing targeted for the second half of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDE251, a potential first-in-class KAT6/7 dual inhibitor development candidate with combination opportunities with multiple programs in the Company&#x2019;s pipeline. IND filing targeted for the second half of 2025.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Development</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Appointed Joshua Bleharski, Ph.D., as Chief Financial Officer. Dr. Bleharski to join IDEAYA from J.P. Morgan, serving most recently as Managing Director and Global Co-Head of Biopharma in the Healthcare Investment Banking group.  Josh spent nearly </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">17 years at J.P. Morgan advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services representing more than $65 billion of value for biotechnology companies worldwide.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Appointed Stu Dorman as Chief Commercial Officer. Mr. Dorman brings over 20 years of global commercialization experience in oncology</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">with prominent biopharmaceutical companies such as Gilead Sciences and Bristol Myers Squibb, where he led multiple commercial launches for products including Trodelvy and Opdivo.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Financial Results</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">As of December 31, 2024, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.1 billion, compared to $632.6 million as of December 31, 2023. The increase was primarily driven from $379.9 million in net proceeds from the sale of common stock shares through at-the-market financings during the year, $283.8 million from an underwritten public offering of common stock and pre-funded warrants to purchase common stock completed in July 2024, partially offset by net cash used in operations. IDEAYA believes that these funds will be sufficient to fund its planned operations into at least 2028.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Subsequent to the reporting period for the year ended December 31, 2024, the Company generated net proceeds of approximately $25.1 million from the sale of shares of its common stock through at-the-market (ATM) offerings in January 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Collaboration revenue for the three months ended December 31, 2024 totaled $7.0 million compared to $3.9 million for the three months ended December 31, 2023. Collaboration revenue was recognized for a $7.0 million milestone payment from GSK that was earned for the IND clearance of IDE275 (GSK959) in October 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development (R&amp;D) expenses for the three months ended December 31, 2024, totaled $140.2 million compared to $38.8 million for the three months ended December 31, 2023. The increase was primarily due to a $75.0 million upfront payment under the license agreement for IDE849 with Hengrui Pharma, higher clinical trial expenses to support the portfolio growth and personnel-related expenses.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative (G&amp;A) expenses for the three months ended December 31, 2024 totaled $11.0 million compared to $7.1 million for the three months ended December 31, 2023. The increase was primarily due to higher personnel-related expenses, higher consulting and legal fees.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The net loss for the three months ended December 31, 2024, was $130.3 million compared to the net loss of $34.0 million for the three months ended December 31, 2023. Total stock compensation expense for the three months ended December 31, 2024, was $9.5 million compared to $4.8 million for the same period in 2023.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The net loss for the year ended December 31, 2024 was $274.5 million compared to $113.0 million for the same period in 2023. Total stock compensation expense for the year ended December 31, 2024, was $34.7 million compared to $18.5 million for the same period in 2023.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">About IDEAYA Biosciences</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality &#x2013; which represents an emerging class of precision medicine targets.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDEAYA's updated corporate presentation is available on its website, at its Investor Relations page: </font><font style="color:#467886;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">https://ir.ideayabio.com/</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements, including, but not limited to, statements related to (i) the timing and content of clinical program updates, regulatory updates and clinical trial data readouts; (ii) the potential therapeutic benefits of IDEAYA therapeutics; (iii) the translation of preliminary clinical trial results into future clinical trial results and/or regulatory approval; (iv) timing of development and regulatory milestones; (v) the timing and potential of registration-enabling trial and readouts for darovasertib in 1L HLA-A2 negative MUM; (vi) the timing of the initiation of Phase 3 trial for darovasertib; (vii) the timing and potential for accelerated FDA approval of darovasertib in MUM; (viii) the timing of expansion in IDE397 and Trodelvy combination trial in MTAP-deletion UC and indication in NSCLC; (ix) the timing of combination trial of IDE397 and IDE892 in patients with MTAP-deletion NSCLC; (x) the potential of a Phase 2 expansion monotherapy dose for IDE161; (xi) the timing of initiating IDE161 and DLL3 TOP1i ADC combination trial; (xii) the timing of IDE161 expansion with KEYTRUDA and combinations with TOP1i ADCs in solid tumors; (xiii) timing of INDs for IDE892, IDE034, IDE251, and IDE849; (xiv) timing of data presentation for IDE275 at medical conference; and (xv) the extent to which IDEAYA&#x2019;s existing cash, cash equivalents, and marketable securities will fund its planned operations. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">dated February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Investor and Media Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences<br>Andres Ruiz Briseno<br>SVP, Head of Finance and Investor Relations <br></font><font style="color:#467886;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">investor@ideayabio.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img107722786_0.jpg" alt="img107722786_0.jpg" style="width:111px;height:78px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Condensed Statements of Operations and Comprehensive Loss</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">in thousands, except share and per share amounts</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.753%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:13.796999999999999%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:13.796999999999999%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:13.796999999999999%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:13.857%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Three Months Ended</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Year Ended</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Collaboration revenue</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7,000</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">3,923</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7,000</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">23,385</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">140,183</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">38,770</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">294,673</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">129,508</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">10,955</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7,068</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">39,302</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">28,306</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">151,138</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">45,838</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">333,975</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">157,814</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(144,138</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(41,915</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(326,975</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(134,429</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Interest income and other income, net</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">13,826</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7,960</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">52,498</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">21,468</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(130,312</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(33,955</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(274,477</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(112,961</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Unrealized gains (losses) on marketable securities</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(3,024</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">1,312</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">250</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">3,433</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Comprehensive loss</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(133,336</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(32,643</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(274,227</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(109,528</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Net loss per share <br>&#160;&#160;&#160;attributable to common<br>&#160;&#160;&#160;stockholders, basic and diluted</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(1.49</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(0.52</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(3.36</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(1.96</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Weighted-average number of shares<br>&#160;&#160;outstanding, basic and diluted</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">87,340,758</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">65,246,361</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">81,678,069</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">57,519,929</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">IDEAYA Biosciences, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Condensed Balance Sheet Data</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">in thousands</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.858%;box-sizing:content-box;"></td>
    <td style="width:1.279%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:19.790999999999997%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:1.279%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:19.790999999999997%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;font-kerning:none;min-width:fit-content;">(Unaudited)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Cash and cash equivalents and short-term and <br>&#160;&#160;&#160;long-term marketable securities</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,082,151</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;font-family:Arial;font-kerning:none;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">632,606</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total assets</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,124,091</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">649,316</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">64,944</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">28,226</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1,124,091</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.13%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">649,316</font></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img107722786_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img107722786_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !. &\# 2(  A$! Q$!_\0
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MGQYXXTB;P=X*CT;5KJYEGO6NO$&M6%A/8VD>^;[6B,Z@X;^?7_@E;^T'=?\
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MO^S,2R@-\(/V P&+ *=V@^#<?,3CG/'- '[W_P#!%S_E%!_P3]_[-?\ A?\
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M*&;]H_Q<TT5I;1RM)\%_BB9&D2%%D,F/#L@WE@2^)'&[.'8?,0#Z'_X),_\
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MV\2ZEI%G:W&KM=:]++J\K7C2DW\TUR"))9&;Z+HKZ0Z0HHHH **** "BBB@
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M)RVEW<K'/I6O>#?"7ANTGN-1M3%)<R*TL:Q,EN8UDB=V\>_X)X?L4Z9^PO\
M!3QM\.H=8M/$/B;XH?M"_'K]HKQYK6GQ30Z?<^)_C3\1=7\46^G6$=RD=P+3
MPWX5;PUX75Y44W4VC3WP1!=[!]XT5T8[%SQ^+KXN=*A0=:;DJ.&@Z="C#:%*
ME&4IU.2G!*$95:E6M)14JM6I4<IRX\IRO#9-E^'R["RKU*6'C;VN*K2KXBM.
@3<JE:M4=DZE6;E.4:<*=&#ERT:5*DHTXE%%%<AZ)_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>idya-20250213.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-12T21:00:59.1322+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ideayabio.com/20250213" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:idya="http://www.ideayabio.com/20250213" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="idya-20250213.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45792782584432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001676725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 13,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IDEAYA Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4268251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5000 Shoreline Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">443-6209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IDYA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6!,+/GS4^8! #"J(P740*R:Y,'D>$GA;&GEPI2J[V])[6*$-KPG;,]MSD^#
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " "C,$U:EXJ[',     3 @
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MB^$_7G\!4$L! A0#%     @ HS!-6@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "C,$U:"IYI@^X
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *,P35J7BKL<P    !,"   +
M      "  8L/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *,P35HZJJ+G0 $
M #P"   /              "  700  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "C,$U:)!Z;HJT   #X 0  &@              @ 'A$0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "C,$U:99!YDAD!  #/
M P  $P              @ '&$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"   0%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="idya-20250213.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="idya-20250213.htm">idya-20250213.htm</File>
    <File>idya-20250213.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "idya-20250213.htm": {
   "nsprefix": "idya",
   "nsuri": "http://www.ideayabio.com/20250213",
   "dts": {
    "inline": {
     "local": [
      "idya-20250213.htm"
     ]
    },
    "schema": {
     "local": [
      "idya-20250213.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_a844f886-be6f-4e3b-ab37-202c1ad9d763",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20250213.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a844f886-be6f-4e3b-ab37-202c1ad9d763",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "idya-20250213.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security 12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ideayabio.com/20250213/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-019314-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-019314-xbrl.zip
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M63VF:@IRN,JW7B-7CDNV#).2Q7%,QFE1%2D[T36MI?U0EX>YQ624L4[&1D2
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M_6PQ^Q+HO06F\P-=MVCH8FIZ/JRY P][G@^+!L=U-.)8L*@P%L-T1SQFT'?
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MJ9L_I^[YC&)VA2D79;?2Q5 ,D]WZVEWY]8ZAIZX*O74_Z%]%EO-H7"-(5<0
MO>;BT(<,;WEQZ/7UH8/);D\UD?)J:*QNBBV]0S<_ 'S+UR7"U;X/B4"%=4A\
M2<99Y29I[GS=T#M?YY&W2T^=ZN5LB(R69J!3EA5QKE)Y3T ^5O$E(.70T40
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M5L^&>O<EEG[\H4C@>_]>Y .Q'*.>@29+!FDY2CZF*,J2!LF 08!JZZ>C78V
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MUX*I"M_,5*// 'DMA[OW>#1@^_+A(<C'W)?]"$@2V-+Y.Q;#&PS#)]@R^FQ
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MK;.Q@*OP)*H^"GT)PMA^-GNLMO$(Z[9+8.@%>"3=$;S,OFU:*)13AS)M0=E
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MW=A*H_S?7I+$HIN:XJ%$,E\.AS):?JU*I/]]($/8+<IA74\)7Q]X$X@P37A
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MU2 9AK_^/U!+ 0(4 Q0    ( *,P35I^0Z/RAQ,  .G!   1
M  "  0    !I9'EA+3(P,C4P,C$S+FAT;5!+ 0(4 Q0    ( *,P35JC:I>O
M:0D  #]P   1              "  ;83  !I9'EA+3(P,C4P,C$S+GAS9%!+
M 0(4 Q0    ( *,P35J\6\9V%RH  .'2 @ /              "  4X=  !I
D9'EA+65X.3E?,2YH=&U02P4&      ,  P"[    DD<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>idya-20250213_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="idya-20250213.xsd" xlink:type="simple"/>
    <context id="C_a844f886-be6f-4e3b-ab37-202c1ad9d763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001676725</identifier>
        </entity>
        <period>
            <startDate>2025-02-13</startDate>
            <endDate>2025-02-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_5080a650-be67-4562-a708-c0174506f6b9">0001676725</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_be4fe8f3-19cd-4308-9f54-72b32d444c76">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_68606d89-c67e-4cac-b63f-567c02e842fd">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_9a372119-1541-4907-a056-ba16b4004863">2025-02-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_33e93ea2-fc5e-429d-8ca8-03bd9b0c74d6">IDEAYA Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_1a776c9e-ad9b-4740-8c96-b64a015b16a3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_9b114dc7-d389-49b8-8898-06760a6433e2">001-38915</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_2d65fe38-2ce0-41d3-b3f4-e66cbda0dd7f">47-4268251</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_ed2fe6ad-13ab-42bf-a31f-07963cf3f87c">5000 Shoreline Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_4175a373-b228-4594-b75d-d1439d19e58e">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_7848364a-b426-4bae-a528-1b452777ed6c">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_d4c56b77-cb4f-4deb-82ab-fb0babff8bc4">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_cf2eebeb-f0c1-4e3f-a69b-5c2424a33434">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_6eb8dd52-db95-41e8-9614-167aa0b70db3">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_6d7e86bd-f523-430c-8706-ace50da3e23c">443-6209</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_2eb28740-2042-445f-ab2c-a0c91d1edcbb">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_e50047a6-7c07-4c73-b684-9d95a0e0e77a">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_6dba4e91-3f84-420d-9e1e-ca2917ce8400">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_ef1d3990-9392-47d4-a276-96148fe18815">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_ea64606a-7380-4661-99d1-62f6a0483ca8">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_5c44f9e8-aa37-438a-9445-d787b885798e">IDYA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_145a09d1-8542-42f6-87ad-9c45057e5aff">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a844f886-be6f-4e3b-ab37-202c1ad9d763"
      id="F_a1be958f-4e60-47c3-ad7c-4735cb80a935">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
